

Hiroyuki Yasuda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2378631/publications.pdf>

Version: 2024-02-01

85
papers

3,444
citations

159358

30
h-index

149479

56
g-index

87
all docs

87
docs citations

87
times ranked

5403
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <i>Lancet Oncology</i> , The, 2012, 13, e23-e31.	5.1	505
2	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	5.8	438
3	Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC. <i>Molecular Cancer Research</i> , 2013, 11, 759-767.	1.5	179
4	Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1086-1090.	0.5	148
5	<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 38789-38803.	0.8	137
6	Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. <i>Cancer Cell International</i> , 2008, 8, 15.	1.8	129
7	Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2017, 77, 2078-2089.	0.4	126
8	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. <i>Cell</i> , 2020, 183, 1420-1435.e21.	13.5	111
9	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. <i>Lung Cancer</i> , 2014, 83, 37-43.	0.9	86
10	β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations. <i>Cancer Research</i> , 2014, 74, 5891-5902.	0.4	76
11	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. <i>Molecular Medicine Reports</i> , 2013, 8, 456-462.	1.1	59
12	Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their in vitro behavior. <i>Stem Cell Research</i> , 2015, 15, 109-121.	0.3	59
13	Activation of EGFR Bypass Signaling by TGFβ Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 162-171.	1.9	54
14	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 106-114.	1.5	54
15	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 6548-6555.	3.2	49
16	TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. <i>Molecular Cancer Research</i> , 2019, 17, 2233-2243.	1.5	49
17	The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. <i>International Journal of Clinical Oncology</i> , 2011, 16, 335-344.	1.0	47
18	Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts. <i>Journal of Pathology</i> , 2019, 249, 193-205.	2.1	47

#	ARTICLE	IF	CITATIONS
19	Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e349-e358.	1.1	45
20	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 90-96.	0.9	44
21	An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1096-1103.	0.5	43
22	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , 2019, 127, 146-152.	0.9	42
23	Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 366-372.	0.9	41
24	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030.	3.3	41
25	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. <i>Oncotarget</i> , 2017, 8, 105479-105491.	0.8	41
26	Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. <i>Lung Cancer</i> , 2017, 109, 45-51.	0.9	39
27	Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. <i>Lung Cancer</i> , 2012, 77, 31-37.	0.9	38
28	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. <i>Cell Reports</i> , 2021, 35, 109218.	2.9	38
29	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 549-559.	1.5	34
30	Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 34, 1137-1145.	1.2	33
31	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 140-146.	0.9	32
32	Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. <i>Journal of Cancer</i> , 2017, 8, 1774-1785.	1.2	31
33	A Case of Non-Small Cell Lung Cancer with Possible Disease Flare on Nivolumab Treatment. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-3.	0.2	28
34	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 740-750.	1.9	27
35	Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers. <i>Oncologist</i> , 2018, 23, 1218-1229.	1.9	27
36	Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model. <i>PLoS Pathogens</i> , 2021, 17, e1009542.	2.1	27

#	ARTICLE	IF	CITATIONS
37	The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition. <i>Molecular Cancer Research</i> , 2010, 8, 1142-1151.	1.5	24
38	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. <i>Journal of Pathology</i> , 2015, 235, 593-605.	2.1	23
39	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 31-38.	1.3	23
40	Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. <i>Lung Cancer</i> , 2018, 119, 25-35.	0.9	22
41	Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3335-3343.	1.0	20
42	Methylation-induced downregulation of TFPI 2 causes TMRSS 4 overexpression and contributes to oncogenesis in a subset of non-small cell lung carcinoma. <i>Cancer Science</i> , 2015, 106, 34-42.	1.7	18
43	Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer. <i>Lung Cancer</i> , 2011, 72, 32-38.	0.9	17
44	Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. <i>Journal of Dermatology</i> , 2017, 44, 818-821.	0.6	16
45	Identification and Characterization of ALK Kinase Splicing Isoforms in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 248-253.	0.5	15
46	Multiple roles of extracellular fibroblast growth factors in lung cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 423-429.	1.4	15
47	Intermittent Exposure to Cigarette Smoke Increases Lung Tumors and the Severity of Emphysema More than Continuous Exposure. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 179-188.	1.4	15
48	The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1330-1334.	1.0	15
49	Studies on the Syntheses of 4, 5-Disubstituted Isoxazoles and their Cleavage Reaction with Sodium Ethoxide. I. <i>Yakugaku Zasshi</i> , 1959, 79, 467-470.	0.0	14
50	Effects of the common polymorphism in the human aldehyde dehydrogenase 2 (ALDH2) gene on the lung. <i>Respiratory Research</i> , 2017, 18, 69.	1.4	14
51	<sc>HSP90</sc> inhibition overcomes <sc>EGFR</sc> amplification-induced resistance to third-generation <sc>EGFR-TKIs</sc>. <i>Thoracic Cancer</i> , 2021, 12, 631-642.	0.8	14
52	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929.	0.4	13
53	Studies on the Synthesis of 4, 5-Disubstituted Isoxazoles and their Cleavage Reaction with Sodium Ethoxide. III. <i>Yakugaku Zasshi</i> , 1959, 79, 836-838.	0.0	12
54	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. <i>International Journal of Oncology</i> , 2015, 46, 430-436.	1.4	12

#	ARTICLE	IF	CITATIONS
55	SHOC2 Is a Critical Modulator of Sensitivity to EGFR TKIs in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , 2021, 19, 317-328.	1.5	12
56	Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors. <i>International Journal of Oncology</i> , 2010, 37, 1537-46.	1.4	10
57	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2017, 14, 3559-3565.	0.8	10
58	Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001). <i>Molecular and Clinical Oncology</i> , 2017, 6, 409-414.	0.4	9
59	Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 172-177.	0.7	8
60	EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib. <i>Internal Medicine</i> , 2018, 57, 1007-1010.	0.3	8
61	Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study. <i>Palliative Medicine</i> , 2021, 35, 943-951.	1.3	8
62	Small cystic insulinoma: Value of arterial stimulation venous sampling. <i>CardioVascular and Interventional Radiology</i> , 1997, 20, 308-310.	0.9	7
63	The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 356-360.	0.8	6
64	A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 513-519.	1.1	6
65	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 356-361.	0.6	6
66	Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 488-490.	0.4	6
67	Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 74-78.	1.5	6
68	Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress. <i>Oncologist</i> , 2021, 26, e2265-e2273.	1.9	6
69	Studies on the Synthesis of 4, 5-Disubstituted Isoxazoles and their Cleavage Reaction with Sodium Ethoxide. II. <i>Yakugaku Zasshi</i> , 1959, 79, 623-627.	0.0	4
70	A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 717-722.	1.1	4
71	Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. <i>Medicine (United States)</i> , 2017, 96, e9081.	0.4	4
72	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1593-1601.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small cell lung cancer cells. <i>Cancer Science</i> , 2020, 111, 3793-3801.	1.7	4
74	Studies on the Color Reaction of Fe ⁺⁺⁺ with Formyldeoxybenzoin. <i>Yakugaku Zasshi</i> , 1953, 73, 185-187.	0.0	3
75	Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer. <i>Internal Medicine</i> , 2018, 57, 2383-2387.	0.3	2
76	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 1-7.	1.0	2
77	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1065-1071.	1.1	1
78	On the Iron^{III} Complex Salt of Formyldeoxybenzoin. <i>Yakugaku Zasshi</i> , 1956, 76, 655-656.	0.0	0
79	Determination of Sulfisoxazole. <i>Yakugaku Zasshi</i> , 1959, 79, 113-115.	0.0	0
80	Sternoclavicular joint osteomyelitis extending to lung abscess complicated by Staphylococcal infective endocarditis. <i>IDCases</i> , 2017, 9, 36-37.	0.4	0
81	Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 679-680.	0.5	0
82	A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19039-e19039.	0.8	0
83	The efficacy and safety of nivolumab in advanced non-small cell lung cancer in clinical practice in Japan: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20577-e20577.	0.8	0
84	Clinical characterization and in silico drug sensitivity prediction model of rare EGFR mutations in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21221-e21221.	0.8	0
85	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 911-918.	0.0	0